GHRS Profile
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for psychiatric and neurological disorders. The company specializes in the development of treatments based on 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), a compound with potential therapeutic benefits for patients with treatment-resistant depression (TRD) and other challenging mental health conditions.
The company’s lead program, GH001, is an inhalable 5-MeO-DMT product candidate. This product has progressed through two Phase 1 clinical trials and a Phase 1/2 clinical trial, focusing on patients suffering from TRD. GH001 is designed to offer a novel approach to treating depression by leveraging the unique properties of 5-MeO-DMT to potentially induce significant therapeutic effects.
In addition to GH001, GH Research is advancing other 5-MeO-DMT-based therapies. GH002 is an injectable formulation currently in preclinical development, aimed at providing alternative delivery methods for 5-MeO-DMT. Similarly, GH003 is an intranasal 5-MeO-DMT product candidate, also in the preclinical phase, designed to offer another method of administration for psychiatric and neurological conditions.
Founded in 2018 and headquartered in Dublin, Ireland, GH Research PLC is positioned at the cutting edge of psychiatric and neurological therapy development. The company's focus on 5-MeO-DMT reflects a commitment to exploring novel treatment options for complex mental health issues, with the potential to address significant unmet needs in the field of mental health and neurology.
|
